MANGOCEUTICALS, INC.
For the period ended Mar 31, 2026. Filed May 19, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 19, 2026
MGRX$0.19-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| For The Three Months Ended · For The Three Months Ended | ||||
|---|---|---|---|---|
| March 31, 2026 · March 31, 2025 | ||||
| (Unaudited) · (Unaudited) | ||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||
| Net loss | $(3,403,141) | $(4,839,489) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation | 250 | 250 | ||
| Issuance of common stock for services | 589,107 | 1,938,500 | ||
| Options vested for stock-based compensation | 1,090,114 | 50,979 | ||
| Amortization of intagible assets | 276,815 | 276,815 | ||
| Amortization of license agreement | 14,523 | 137,927 | ||
| Operating lease right of use asset | 13,800 | 15,719 | ||
| (Increase) decrease in operating assets: | ||||
| Prepaid expenses - related party | 120 | - | ||
| Prepaid expenses | 6,124 | (83,214) | ||
| Deposits | 16,942 | - | ||
| (Decrease) increase in operating liabilities: | ||||
| Accounts payable and accrued liabilities | 113,118 | 340,678 | ||
| Operating lease right of use liabilities | (13,800) | (17,249) | ||
| Payroll tax liabilities | (6,124) | - | ||
| Other liabilities | (9,191) | (121,576) | ||
| Other liabilities -related parties | - | 25,879 | ||
| NET CASH USED IN OPERATING ACTIVITIES | (1,311,343) | (2,274,781) | ||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||
| Proceeds from sales of common stock | - | 655,000 | ||
| Proceeds from sales of series B convertible preferred stock | - | 1,150,000 | ||
| Proceeds from exercise of warrants | - | 480,000 | ||
| NET CASH PROVIDED BY FINANCING ACTIVITIES | - | 2,285,000 | ||
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | ||||
| End of period | (1,311,343) | 10,219 | ||
| CASH AND CASH EQUIVALENTS: | ||||
| Beginning of period | 1,486,338 | 58,653 | ||
| Effects of currency translation on cash and cash equivalents | (433) | 7,624 | ||
| End of period | $174,562 | $76,496 | ||
| Supplemental disclosure of cash flow information: | ||||
| Cash paid for income taxes | $ | - | $ | - |
| Cash paid for interest | $ | - | $ | - |
| Supplemental schedule of non-cash investing and financing activities: | ||||
| Issuance of common stock for master distribution agreement | $ | - | $6,713,000 | |
| Series C Convertible Preferred accrued dividend | $ | - | $294,000 | |
| Issuance of common stock for settlement of note payable | $ | - | $150,000 | |
| Issuance of common stock for conversion of Series B Convertible Preferred | $ | - | $1,581,812 | |
Mangoceuticals, Inc.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.